Charles River Laboratories International, Inc. (NYSE:CRL) Shares Bought by Creative Planning

Creative Planning grew its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 4.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,672 shares of the medical research company’s stock after purchasing an additional 180 shares during the period. Creative Planning’s holdings in Charles River Laboratories International were worth $920,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of CRL. Oregon Public Employees Retirement Fund lifted its holdings in shares of Charles River Laboratories International by 1.0% during the 2nd quarter. Oregon Public Employees Retirement Fund now owns 4,424 shares of the medical research company’s stock worth $914,000 after acquiring an additional 45 shares during the period. American Trust lifted its holdings in shares of Charles River Laboratories International by 5.9% during the 2nd quarter. American Trust now owns 976 shares of the medical research company’s stock worth $202,000 after acquiring an additional 54 shares during the period. Tortoise Investment Management LLC lifted its holdings in shares of Charles River Laboratories International by 77.0% during the 2nd quarter. Tortoise Investment Management LLC now owns 131 shares of the medical research company’s stock worth $27,000 after acquiring an additional 57 shares during the period. Mitchell & Pahl Private Wealth LLC lifted its holdings in shares of Charles River Laboratories International by 2.0% during the 2nd quarter. Mitchell & Pahl Private Wealth LLC now owns 3,154 shares of the medical research company’s stock worth $652,000 after acquiring an additional 62 shares during the period. Finally, Empirical Finance LLC raised its holdings in Charles River Laboratories International by 5.3% in the first quarter. Empirical Finance LLC now owns 1,272 shares of the medical research company’s stock valued at $345,000 after buying an additional 64 shares during the period. 98.91% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

CRL has been the topic of several research reports. JPMorgan Chase & Co. lowered shares of Charles River Laboratories International from an “overweight” rating to a “neutral” rating and cut their price target for the company from $270.00 to $205.00 in a report on Thursday, August 8th. The Goldman Sachs Group cut their price target on shares of Charles River Laboratories International from $290.00 to $250.00 and set a “buy” rating on the stock in a report on Thursday, August 8th. Redburn Atlantic initiated coverage on shares of Charles River Laboratories International in a report on Monday, October 14th. They issued a “sell” rating and a $151.00 price target on the stock. CLSA initiated coverage on shares of Charles River Laboratories International in a report on Wednesday, October 23rd. They issued an “underperform” rating and a $167.00 price target on the stock. Finally, StockNews.com upgraded shares of Charles River Laboratories International from a “hold” rating to a “buy” rating in a report on Wednesday, October 16th. Three investment analysts have rated the stock with a sell rating, ten have given a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $209.00.

Charles River Laboratories International Stock Up 1.3 %

CRL stock opened at $180.96 on Friday. Charles River Laboratories International, Inc. has a twelve month low of $166.87 and a twelve month high of $275.00. The company has a current ratio of 1.58, a quick ratio of 1.21 and a debt-to-equity ratio of 0.65. The company has a market capitalization of $9.34 billion, a P/E ratio of 21.67, a PEG ratio of 6.22 and a beta of 1.36. The firm has a 50 day simple moving average of $193.72 and a 200-day simple moving average of $209.45.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings results on Wednesday, August 7th. The medical research company reported $2.80 earnings per share for the quarter, topping analysts’ consensus estimates of $2.39 by $0.41. The business had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $1.03 billion. Charles River Laboratories International had a net margin of 10.83% and a return on equity of 14.96%. On average, equities research analysts predict that Charles River Laboratories International, Inc. will post 10.01 earnings per share for the current fiscal year.

Charles River Laboratories International declared that its board has approved a share repurchase program on Wednesday, August 7th that allows the company to repurchase $1.00 billion in shares. This repurchase authorization allows the medical research company to reacquire up to 9.6% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company’s board of directors believes its stock is undervalued.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).